en · de · es · fr · pt
aod-9604-notes.peptides6155.com › Guide › Background And Research Context — Complete Guide

Background And Research Context — Complete Guide

By Editorial Desk · published 2026-03-24 · last reviewed 2026-04-15 · Guide

Everything below concerns peptide research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-04-15. Numbers and descriptions here follow the published literature rather than marketing material.

Background And Research Context

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Aod-9604 at a glance

PropertyValueNotes
Common synonymhGH fragment 176-191Refers to the C-terminal segment
AppearanceWhite to off-white powderTypically supplied lyophilized
SolubilitySoluble in water and aqueous buffersConfirm with technical data
Typical storage temperature-20 °C for dry powderProtect from moisture and light
Common analytical methodRP-HPLC with UV detectionOften paired with mass spectrometry

Background from the literature

SHG being a coherent process (spatially and temporally), it keeps information on the direction of the excitation and is not emitted isotropically. It is mainly emitted in forward direction (same as excitation), but can also be emitted in backward direction depending on the phase-matching condition. Indeed, the coherence length beyond which the conversion of the signal decreases is:

== Purpose == Without trichrome staining, discerning one feature from another can be extremely difficult. Smooth muscle tissue, for example, is hard to differentiate from collagen. A trichrome stain can colour the muscle tissue red, and the collagen fibres green or blue. Liver biopsies may have fine collagen fibres between the liver cells, and the amount of collagen may be estimated based on the staining method. Trichrome methods are now used for differentiating muscle from collagen, pituitary alpha cells from beta cells, fibrin from collagen, and mitochondria in fresh frozen muscle sections, among other applications. It helps in identifying increases in collagenous tissue (i.e., fibrotic changes) such as in liver cirrhosis and distinguishing tumours arising from muscle cells and fibroblasts.

=== Achondrogenesis type 2 === Several kinds of mutations in the COL2A1 gene are responsible for achondrogenesis type 2. These include missing pieces of the gene, substitution of the amino acid glycine with another amino acid, or changes that result in truncated proteins. All these mutations disrupt the production of mature type II collagen, affecting tissues rich in this collagen.

== Integrins == Integrins function as the major cell receptor for extracellular matrix protein. These receptors comprise an α and β transmembrane subunit, which are noncovalently bound. Collagen binding is primarily provided by integrins α1β1, α2β1, α10β1 and α11β1. Integrin α1β1 binds to collagen via the MIDAS motif in the α subunit I domain. It preferentially binds collagens IV, VI and type XIII collagen, but also fibril-forming collagens. Specific binding sites in collagen I and IV have been identified. This receptor is situated mainly on mesenchymal cells. Functions include: fibroblast proliferation; regulation of collagen synthesis and MMP expression; response to renal injury. Integrin α2β1 preferentially binds fibril-forming collagens. Specific binding sites in collagen I and III have been identified. Integrin α2β1 is expressed mainly on epithelial cells and platelets. Functions include: platelet adhesion - the most abundant receptor for collagen in platelets; branching morphogenesis; mast cell activation; keratinocyte adhesion and it is the main regulator of cell migration. Integrin α10β1 preferentially binds collagens IV and VI, but also collagen II. It is expressed on chondrocytes and cardiac muscle. Involved in growth plate morphogenesis and function. Integrin α11β1 is expressed by mesenchymal cells in some parts of embryo during its development and also in muscles in adults: it preferably binds fibrillar collagen. Integrin receptors capable of collagen binding could, according to results of (Garnotel R et al.

Sources: en.wikipedia.org

Related pages on this site

Reference notes

=== Limits on green industrial policy === The law phases out tax credits passed in the Biden-era Inflation Reduction Act. Credits will continue for wind and solar projects which either start construction by June 2026 or which go online by December 2027, under "safe harbor" and expanded "foreign entity of concern" provisions. The OBBBA directed the Treasury Department to issue more stringent standards for documenting supply chains and construction of solar and wind facilities in August 2025. The OBBBA also severely limits the credits' transferability in dedicated markets. Electric vehicle tax credits would be phased out by September 2025, and EV charging tax credits would be phased out by June 2026. Green hydrogen production credits are terminated by December 2027, rather than 2033. Home electrification credits are terminated by December 2025. Advanced manufacturing, carbon sequestration, biofuel, and nuclear power credits remain largely intact (nuclear power even gets a new 10% bonus credit), subject to the aforementioned foreign entity of concern rules. Fees on methane emissions that polluters have to pay the government would be postponed for 10 years, while tax credits for biofuels would be extended an additional four years to 2031. The law also rescinds various funds, appropriated in the IRA. These include:

TikTok tends to appeal to younger users, as 41% of its users are between the ages of 16 and 24. As of 2021, these individuals are considered Generation Z. TikTok's geographical use in 2019 has shown that 43% of new users were from India before the social platform was banned in the country. But adults have also seen growth on TikTok. The share of US adults who regularly get news from TikTok hit 5% in 2025. By July 2023, TikTok has become the primary news source for British teenagers on social media, with 28% of 12 to 15-year-olds relying on the platform, while traditional sources like BBC One/Two are more trusted at 82%, according to a report by UK regulator Ofcom. As of the first quarter of 2022, there were over 100 million monthly active users in the United States and 23 million in the UK. The average user, daily, was spending 1 hour and 25 minutes on the app and opening TikTok 17 times. Out of TikTok's top 100 male creators, a 2022 analysis reported 67% were white, with 54% having near-perfect facial symmetry.

=== Category:EC 2.8 (transfer sulfur-containing groups) === EC 2.8.1.1: Thiosulfate sulfurtransferase EC 2.8.1.2: 3-mercaptopyruvate sulfurtransferase EC 2.8.1.3: Thiosulfate—thiol sulfurtransferase EC 2.8.1.4: tRNA uracil 4-sulfurtransferase EC 2.8.1.5: Thiosulfate—dithiol sulfurtransferase EC 2.8.1.6: Biotin synthase EC 2.8.1.7: Cysteine desulfurase EC 2.8.1.8: Lipoyl synthase EC 2.8.1.9: Molybdenum cofactor sulfurtransferase EC 2.8.1.10: Thiazole synthase EC 2.8.1.11: Molybdopterin synthase sulfurtransferase EC 2.8.1.12: Molybdopterin synthase EC 2.8.1.13: tRNA-uridine 2-sulfurtransferase EC 2.8.1.14: tRNA-5-taurinomethyluridine 2-sulfurtransferase EC 2.8.1.15: tRNA-5-methyluridine(54) 2-sulfurtransferase

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.

Is AOD-9604 the same as human growth hormone?

No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.

Has AOD-9604 been approved for weight loss?

Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.

Is AOD-9604 approved for medical use?

No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.

Network